7. Predictive value for efficacy of adjuvant chemotherapy Concordant data with SWOG 8814 (Albain, Lancet Oncol, 2009) Paik, JCO, 2006 Interaction test, p=0.038 NSABP-B20 trial
8.
9. Mammaprint 70 genes signature Associated with high risk of metastatic relapse
18. Levels of evidence (Simon-Hayes) Consistent retrospective data from prospective clinical studies could define a level I evidence…. pending a prospective validation, like observational cohort (speaker’s opinion)
19. Does Recurrence score add to conventional parameters ? I: adjuvant online Recurrence score is adding information to AOL Tang, BCRT
20. Does Recurrence score add to conventional parameters ? I: « optimal » IHC score (ER, PR, Her2, KI67) Since RS includes ER, PR, Her2 and KI67, does it provide additional information ?
21. Correlation between RS and (ER, PR, Her2, proliferation) RS correlates with standard pathological parameters but… the level of correlation is not high
23. Does RS provide additional information as compared to standard parameters ? Comparison with AOL: Yes Comparison with ER/PR/Her2/KI67 : this is NOT the righ question since: the level of evidence for KI67 is not I, at least for the prediction to adjuvant chemotherapy (speaker’s opinion) Current status : the equivalency between RS and (ER,PR,Her2,KI67), together with the predictive value of KI67 are still research hypotheses
24.
25.
26.
27.
28. Genomic predictors for treatment efficacy: Conventional treatment Predictor Treatment Reference Stroma metagene chemotherapy Farmer, Nat Med TOP2A metagene anthracyclines Desmedt, ASCO DLD30 paclitaxel > FAC Hess, J Clin Oncol SET index endocrine therapy Symmans, J Clin Oncol MX1 metagene anthracyclines Andre, ASCO
29. Genomic predictors for treatment efficacy: targeted therapies Functional pathways Target detection Quantification of PI3K activation / GE array Loi, PNAS, 2010 B. Hennessy, CCR, 09
30.
31. Current model Academic hospital Tumor block Multiplex assay: CLIA lab or biomarker company Limitation: multiplicity of multigene assays will make non feasible the outsoursing Solution: run whole genome arrays in academic centers (with reimbursement of IP)
32. Are whole genome arrays feasible in the context of daily practice ?
33. Genomic driven chemotherapy: REMAGUS 04 trial Breast adenocarcinoma Conservative surgery not feasible FEC > Docetaxel Primary endpoint: pCR Secondary endpoint : feasibility of whole genome array in academic centers in the context of daily practice Funding: French NCI DLD30+: Paclitaxel >FEC DLD30-/TOP2A+: FEC>docetaxel DLD30-/TOP2A-: Docetaxel / cape RNA extraction, QC, hybridization Affy U133plus2, bioinformatics If QC genomic: inclusion
34. Remagus04 Trial : January-September 2009 <10% if biopsy is guided by ultrasonography Necessary ? Current status: N=200 Interim analysis
35. Robustness: comparison between ER status and ESR1 expression 205225_at Gene expression array is accurate to define ER status in the context of daily practice MD Anderson correlation Remagus04 Correlation Oestrogen receptor:ESR1 Receptor status Probeset Receptor status Probeset 205225_at 0,77 1·00 0,80 1,00 211233_x_at 0,53 0,78 0,60 0,71 211234_x_at 0,38 0,62 0,56 0,62 211235_s_at 0,55 0,79 0,50 0,63 211627_x_at 0,17 0,05 0,07 0,14 215551_at – 0,12 – 0,06 0,49 0,61 215552_s_at 0,62 0,8 0,54 0,70 217163_at – 0,21 – 0,14 0,18 0,21 217190_x_at 0,47 0,61 0,48 0,58
36. SAFIR01 trial Phase I/II FGFR1 inh Rare events Phase I Phase II NOTCH inh Started or to start soon Under discussion Prospective evaluation of Integrated biology for treatment decision Cooperative group (FNCLCC) Biopsy of metastatic sites Frozen sample CGH / hot spot mutations (PIK3CA/AKT) n=400 PAK inh PAK1 amp Molecular screening: Which candidate target ? Clinical trials: Is the target relevant ? FGFR1 FGFR2 FGF4 amp Phase II PI3K inh Or everolimus NOTCH amp Phase II CBDCA +/- BSI201 Genetic instability PAK1 ampli PIK3CA / AKT / PTEN alteration bevacizumab VEGFA amplification Others Funding: French NCI
37. SAFIR01 trial: logistics Patient inclusion DNA extraction Hybridization Hot spot mutations Target identification Quantification genetic instability Weekly tumor board Investigation center Genomic unit Curie (Affy 6.0) Genomic unit Gustave roussy (Agilent 4*44) Genomic unit Lyon (Affy 6.0) Bioinformatics Gustave Roussy